Compare FXNC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | VNDA |
|---|---|---|
| Founded | 1907 | 2002 |
| Country | United States | United States |
| Employees | 308 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.1M | 231.0M |
| IPO Year | 2012 | 2005 |
| Metric | FXNC | VNDA |
|---|---|---|
| Price | $28.75 | $3.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $33.00 | $11.50 |
| AVG Volume (30 Days) | 12.7K | ★ 1.2M |
| Earning Date | 10-23-2026 | 10-28-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 96.00 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | $7,717,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $7.52 | $12.05 |
| Revenue Next Year | $4.62 | $30.61 |
| P/E Ratio | $15.02 | ★ N/A |
| Revenue Growth | 7.40 | ★ 8.72 |
| 52 Week Low | $23.71 | $3.57 |
| 52 Week High | $33.24 | $9.91 |
| Indicator | FXNC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 32.18 |
| Support Level | $28.80 | N/A |
| Resistance Level | $30.57 | $5.49 |
| Average True Range (ATR) | 0.89 | 0.23 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 16.91 | 0.00 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.